The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts

3d ago, source:

In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average ...

Intra-Cellular Therapies Prices Public Offering of Common Stock

8d ago, source:

Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and ...

Intra-Cellular Therapies gets grant for patent granted for amorphous solid dispersion of ITI-007 tosylate salt

1d ago, source: Pharmaceutical Technology

Discover the groundbreaking patent by Intra-Cellular Therapies Inc for stable amorphous solid dispersions of ITI-007 tosylate salt. Learn about the innovative methods, compositions, and potential ...

Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study

on MSN ago, source:

Intra-Cellular Therapies Inc (NASDAQ:ITCI) unveiled on Tuesday topline results from Study 501 evaluating lumateperone 42 mg ...

Intra-Cellular Therapies (ITCI) Price Target Increased by 7.08% to 91.50

9d ago, source: Fintel on MSN

The average one-year price target for Intra-Cellular Therapies (NasdaqGS:ITCI) has been revised to 91.50 / share. This is an ...

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

9d ago, source:

Positive results from two Intra-Cellular Therapies phase 3 studies show lumateperone's potential as adjunctive therapy for ...

Intra-Cellular Looks to Raise $500M in Public Offering Following Phase III MDD Win

7d ago, source: BioSpace

On the heels of a late-stage victory for its antipsychotic drug Caplyta in patients with major depressive disorder, ...

Drugmaker Intra-Cellular Soars as Depression Trial Succeeds

on MSN ago, source:

Intra-Cellular Therapies Inc. soared the most in more than two years after its top-selling drug succeeded in a trial of major ...

Intra-Cellular sets up $500m offer on Caplyta depression win

9d ago, source: pharmaphorum

Buoyed by the new data, Intra-Cellular promptly filed a $500 million stock offering to help fund what could be a big ...

Another Caplyta trial win moves Intra-Cellular closer to FDA filing in major depressive disorder

9d ago, source: FiercePharma

Intra-Cellular Therapies has unveiled another positive late-stage trial readout for Caplyta, taking another step toward a ...

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)

1d ago, source:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) ...

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

9d ago, source:

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the ...